glp 1 agonist alternative Ozempic Alternatives Flood Medical Aesthetics Market Despite Concerns of Long-Term Sustainability GLP-1 Drug Savings: A Complete

Food and Drug Administration (FDA) to treat individuals with type 2 diabetes mellitus and obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one other weight-related medical condition

Involvement of glucagon-like peptide-1 in the regulation of selective excretion of sodium or chloride ions by the kidneys

Future Potential : The robust pipeline of increasingly effective agents, combined with emerging oral formulations and potential cost reduction strategies, suggests that current limitations may be surmountable with continued innovation and policy development

doi: 10.1056/NEJMoa2501006 91 ParabPChaudharyPMukhtarSMoradiAKodaliAOkoyeCet al

Eli Lilly plans to introduce Mounjaro (tirzepatide) in India by 2025, while Biocon has made regulatory filings for GLP-1 receptor agonists in various markets, including India, to expand its portfolio in the obesity and diabetes treatment segments

For one, they may allow people with knee osteoarthritis to avoid or delay knee replacement surgery